These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33434054)

  • 1. Graft Versus Leukemia: Current Status and Future Perspectives.
    O'Neill AT; Chakraverty R
    J Clin Oncol; 2021 Feb; 39(5):361-372. PubMed ID: 33434054
    [No Abstract]   [Full Text] [Related]  

  • 2. T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect.
    Cruz CR; Bollard CM
    Haematologica; 2015 Jun; 100(6):709-19. PubMed ID: 26034113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introduction to a review series on strategies to improve GVL effects.
    Zeiser R
    Blood; 2018 Mar; 131(10):1039. PubMed ID: 29358178
    [No Abstract]   [Full Text] [Related]  

  • 4. New immunotherapy-based approach in allogeneic hematopoietic stem cell transplantation.
    Maeda Y
    Int J Hematol; 2018 Feb; 107(2):129. PubMed ID: 29260506
    [No Abstract]   [Full Text] [Related]  

  • 5. Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies.
    Schmid C; Kuball J; Bug G
    J Clin Oncol; 2021 Feb; 39(5):397-418. PubMed ID: 33434060
    [No Abstract]   [Full Text] [Related]  

  • 6. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants.
    Randolph SS; Gooley TA; Warren EH; Appelbaum FR; Riddell SR
    Blood; 2004 Jan; 103(1):347-52. PubMed ID: 12969970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graft-versus-host and graft-versus-leukemia reactions: a summary of the Seventh International Symposium held in Garmisch-Partenkirchen, Germany, February 22nd-25th, 2006, Tolerance and Immunity, an update on lymphoid malignancies.
    Munker R; Reibke R; Kolb HJ
    Bone Marrow Transplant; 2006 Nov; 38(9):593-607. PubMed ID: 16980992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of GVHD without losing GVL effect: windows of opportunity.
    Zhang P; Chen BJ; Chao NJ
    Immunol Res; 2011 Apr; 49(1-3):49-55. PubMed ID: 21136200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indications and donor selections for allogeneic stem cell transplantation in children with hematologic malignancies.
    Handgretinger R; Kurtzberg J; Egeler RM
    Pediatr Clin North Am; 2008 Feb; 55(1):71-96, x. PubMed ID: 18242316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The allogeneic HLA-DP-restricted T-cell repertoire provoked by allogeneic dendritic cells contains T cells that show restricted recognition of hematopoietic cells including primary malignant cells.
    Laghmouchi A; Hoogstraten C; van Balen P; Falkenburg JHF; Jedema I
    Haematologica; 2019 Jan; 104(1):197-206. PubMed ID: 30237261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing the incidence and severity of acute graft-versus-host disease.
    Dosal J; Kirsner RS
    J Invest Dermatol; 2012 Jan; 132(1):6. PubMed ID: 22158604
    [No Abstract]   [Full Text] [Related]  

  • 12. Adoptive allogeneic immunotherapy--history and future perspectives.
    Schleuning M
    Transfus Sci; 2000 Oct; 23(2):133-50. PubMed ID: 11035275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minor histocompatibility antigens as targets of graft-versus-leukemia reactions.
    Falkenburg JH; Marijt WA; Heemskerk MH; Willemze R
    Curr Opin Hematol; 2002 Nov; 9(6):497-502. PubMed ID: 12394171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenomics in hematopoietic transplantation: novel treatment strategies.
    Engel N; Rank A
    Epigenomics; 2011 Oct; 3(5):611-23. PubMed ID: 22126249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction.
    Miller JS; Warren EH; van den Brink MR; Ritz J; Shlomchik WD; Murphy WJ; Barrett AJ; Kolb HJ; Giralt S; Bishop MR; Blazar BR; Falkenburg JH
    Biol Blood Marrow Transplant; 2010 May; 16(5):565-86. PubMed ID: 20152921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards immunogene therapy of hematological malignancies.
    Ivanov R; Hagenbeek A; Ebeling S
    Exp Hematol; 2006 Mar; 34(3):251-63. PubMed ID: 16543059
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of invariant NKT cells in allogeneic hematopoietic stem cell transplantation.
    Karadimitris A; Chaidos A
    Crit Rev Immunol; 2012; 32(2):157-71. PubMed ID: 23216613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.
    Stenger EO; Turnquist HR; Mapara MY; Thomson AW
    Blood; 2012 May; 119(22):5088-103. PubMed ID: 22403259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expansion in clinical application of hematopoietic stem cell transplantation--present status of reduced-intensity stem cell transplantation].
    Harada M
    Nihon Naika Gakkai Zasshi; 2004 Mar; 93(3):465-70. PubMed ID: 15052804
    [No Abstract]   [Full Text] [Related]  

  • 20. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.